NeuroPace
Clinical trials sponsored by NeuroPace, explained in plain language.
NeuroPace makes an implantable brain-responsive neurostimulation device for epilepsy.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Brain implant shows promise for Hard-to-Treat seizures in rare epilepsy Results expected Nov 2026 (estimated)
- Brain implant that fires at seizures tested in teens Results expected Feb 2027 (estimated)
-
Brain device zaps seizures in Tough-to-Treat epilepsy
Disease control CompletedThis study tested a brain implant (RNS System) that delivers targeted electrical stimulation to the thalamus to reduce seizures in people aged 12 and older with drug-resistant idiopathic generalized epilepsy. The goal was to see if the device is safe and effective at cutting down…
Sponsor: NeuroPace • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Brain implant device tracked for 5 years in epilepsy patients
Disease control CompletedThis study followed 345 people with epilepsy who already had a brain implant called the RNS System. The goal was to see how safe and effective the device is over 5 years in everyday medical practice. Researchers measured side effects, seizure reduction, and how well doctors could…
Sponsor: NeuroPace • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC